IL17A and pulmonary arterial hypertension: However, in a post hoc analyses of the rituximab-treated group, patients bearing increases in the biomarkers rheumatoid factor, IL-2 and IL-17 showed significant lower pulmonary vascular resistance in comparison to patients that did not have these alterations and received antibody therapy, and, therefore, raise awareness for patient selection for B-cell depletion therapies in SSc-PAH (Zamanian et al., 2021; Zhang and Michelakis, 2021).